#1
|
|||
|
|||
![]() Ïðèâåòñòâóþ âñåõ ó÷àñòíèêîâ ôîðóìà.
Ìîÿ æåíà ïÿòü ëåò íàçàä ïåðåæèëà òðàâìó ïîçâîíî÷íèêà (ïåðåëîì â ãðóäíîì è ïîÿñíè÷íîì îòäåëå) ñïóñòÿ ïîëãîäà ïîÿâèëñÿ ñàõàðíûé äèàáåò 1 ãî òèïà, ïîñëåäíåå âðåìÿ ìó÷àþò îñòðûå áîëè â íîãàõ ïðèåìóùåñòâåííî â íî÷íîå âðåìÿ. Ìåñòíàÿ ìåäåöèíà ôèëîñîâñêè ðàçâîäèò ðóêàìè "à âû ÷åãî õîòåëè, ñ òàêèìè òî áîëåçíÿìè...". Åé âñåãî 25, ÿ íå âåðþ, ÷òî âñå ïîòåðÿíî, îäíàêî íå èìåþ íè ìàëåéøåãî ïðåäñòàâëåíèÿ êóäà ñ ýòèì ìîæíî îáðàòèòüñÿ. Ïîäñêàæèòå ÷òî äåëàòü, áîëè óæå íåñòåðïèìûå, îáåçáîëèâàþùèå íå ïîìîãàþò, ìàññàæ ñíèìàåò áîëü áóêâàëüíî íà íåñêîëüêî ìèíóò. |
#2
|
|||
|
|||
Óâàæàåìûé ãîñïîäèí Íàóìîâ!
Èíòåðåñíî áû çíàòü åùå íåñêîëüêî ìîìåíòîâ: 1. ×òî áûëà çà òðàâìà? Êàêîé èìåííî ïåðåëîì ïîçâîíî÷íèêà, êàê ëå÷èëè è êàêèå ïîñëåäíèå ðåçóëüàòû ÌÐÒ åñëè äåëàëè? 2. Êîìïåíñèðîâàí ëè ñàõàðíûé äèàáåò? 3. Êàêàÿ ÷àñòü íîã áîëèò è õàðàêòåðèñòèêà áîëè. Åñòü ëè áîëè ïðè õîäüáå?  êàêîì ïîëîæåíèè òåëà ñèëüíåå áîëèò? Ñîïðîâîæäàåòñÿ ëè áîëü îíåìåíèåì è/èëè ñóäîðîãàìè? 4. Åñòü ëè ïàòîëîãèÿ âåí íèæíèõ êîíå÷íîñòåé? 5. Êàêèå îáñëåäîâàíèÿ ïî ýòîìó ïîâîäó äåëàëè? Ìîæåò êîëëåãè åù¸ ÷åãî äîïîëíÿò.... |
#3
|
||||
|
||||
Ïðåæäå ÷åì çàíèìàòüñÿ íåâðîëîãè÷åñêîé äèàãíîñòèêîé , ñ÷èòàþ ÍÅÎÁÕÎÄÈÌÛÌ, ïðåæäå âñåãî èñêëþ÷èòü äèàáåòè÷åñêóþ àíãèîïàòèþ.
Äàëåå -âñå îñòàëüíîå. Íå ëèøíå èññëåäîâàòü êðîâü íà óðîâåíü B12.Cäåëàòü EMG.è äàëåå/ èëè ïàðàëëåëüíî/ ãðàìîòíîå íåâðîëîãè÷åñêîå è îðòîïåäè÷åñêîå îáñëåäîâàíèå.
__________________
doctor Ðolonsky israel Ñíèìêè ñìîòðþ òîëüêî â ïðÿìîì ïîêàçå.,áåç íåîáõîäèìîñòè ñêà÷èâàíèÿ. Ïðîñüáà ïîêàçûâàòü ñíèìêè â ïðàâèëüíîì ïîëîæåíèè. |
#4
|
||||
|
||||
Åù¸ õîòåëîñü áû ñïðîñèòü, ñêîëüêî âðåìåíè ïðîøëî ìåæäó òðàâìîé è ïîÿâëåíèåì áîëåé? Åñòü ëè êðîìå áîëåé íàðóøåíèå äâèæåíèé, ñëàáîñòü â íîãàõ, íàðóøåíèå ÷óâñòâèòåëüíîñòè (åñëè åñòü, òî îïèøèòå ìàêñèìàëüíî ïîäðîáíî).
Õàðàêòåð áîëåé? Æãó÷èå, ðàñïðîñòðàí¸ííûå èëè ïðîñòðåëû, óçêî ëîêàëèçîâàííûå? Åñëè ëîêàëèçîâàííûå, òî ãäå? Êàêèìè íàðóøåíèÿìè ñîïðîâîæäàëàñü òðàâìà ïîçâîíî÷íèêà èçíà÷àëüíî? Ïîêà âðîäå âñ¸, ÷òî ïðèõîäèò â ãîëîâó. |
#5
|
|||
|
|||
Öèòàòà:
Âîò äèàáåòè÷åñêàÿ ïîëèíåéðîïàòèÿ... ![]() Êîíå÷íî å¸ íàäî èñêëþ÷èòü, íî ïî÷åìó èìåííî â ïåðâóþ î÷åðåäü? ÇÛ: ñïàñèáî çà äîïîëíåíèå íà ñ÷¸ò Â12 ![]() |
#6
|
||||
|
||||
Óâàæàåìûå êîëëåãè!
Íå ñîâñåì ïðàêòè÷íî ðåêîìåíäîâàòü ïàöèåíòó îïðåäåëèòü ñîäåðæàíèå Â12 â êðîâè: âî-ïåðâûõ, ýòî âñå-òàêè ÐÎÑÑÈß, ãäå åùå ïîèñêàòü ñëåäóåò êàêàÿ èç ëàáîðàòîðèé äåëàåò òàêîé àíàëèç; âî-âòîðûõ â ïîñëåäíåì ðóêîâîäñòâå ïî ãåìàòîëîãèè ýêñïåðò ïî ìåãàëîáëàñòíûì àíåìèÿì Ralph Carmen ïðèâîäèò äàííûå, ÷òî 30-40% ëþäåé ñ íèçêèì êîáàëàìèíîì (ìåíåå 250 íã/ë) è 70% ñ ïîíèæåííî-íîðìàëüíûì (250-350) ÿâëÿþòñÿ áåññèïìòîìíûìè è ê òîìó æå ìåòàáîëè÷åñêè "äîñòàòî÷íûìè", ÷òî îïðåäåëÿåòñÿ íîðìàëüíûì ñîäåðæàíèåì ãîìîöèñòåèíà è ìåòèëìàëîíàòà â êðîâè. Íåäàâíÿÿ ïóáëèêàöèÿ â BLOOD ñ àìåðèêàíñêîãî àìáóëàòîðíîãî çâåíà âîîáùå ïîêàçûâàåò, ÷òî êëèíè÷åñêàÿ êàðòèíà + ïðîáíîå ëå÷åíèå = ëó÷øàÿ òàêòèêà, ÷åì îïîðà íà ëàá. èññëåäîâàíèÿ. Ïðèâåäó òåçèñû ïîëíîñòüþ (âûäåëåíî ìíîé): Cobalamin-responsive disorders in the ambulatory care setting: unreliability of cobalamin, methylmalonic acid and homocysteine testing Lawrence R Solomon Department of Medicine, Yale University Health Sevices, New Haven, CT, USA; Section of Hematology, Department of Medicine, Yale University School of Medicine, New Haven, CT, USA Early recognition of cobalamin (Cbl)-responsive disorders in the ambulatory care setting is essential to prevent irreversible neurologic deficits. However, diagnostic algorithms using Cbl, methylmalonic acid (MMA) and homocysteine (HCys) measurements reflect studies in academic centers and their negative predictive values have not been established. Thus, records of 456 ambulatory patients evaluated for Cbl deficiency at a staff model HMO were reviewed. Pretherapy Cbl, MMA and HCys values in individual patients varied by 23%, 23% and 17% respectively over 2-6 weeks. Hematologic or neurologic responses to pharmacologic doses of Cbl occurred in 37 of the 95 evaluable patients. In these patients, pretherapy Cbl, MMA and HCys values were normal in 54%, 23% and 50% respectively. If therapy had been restricted to symptomatic patients with both low or intermediate Cbl levels and increased metabolite values, 63% of responders would not have been treated. 25 patients did not respond to treatment, including 5 of 11 patients (45%) with low Cbl; 22 of 49 patients (45%) with high MMA; and 13 of 30 patients (43%) with high HCys values. It is concluded that Cbl, MMA and HCys levels fluctuate with time and neither predict nor preclude the presence of Cbl-responsive hematologic or neurologic disorders. |
#7
|
|||
|
|||
Êàêèå îáñëåäîâàíèÿ Âàøåé æåíå ïðîâîäèëèñü? Ïðîâîäèëàñü ëè ñòèìóëÿöèîííàÿ ýëåêòðîìèîãðàôèÿ íèæíèõ êîíå÷íîñòåé? Åñëè íåò, òî ÿ áû ïîðåêîìåíäîâàë ñäåëàòü ýòî îáñëåäîâàíèå è íàïèñàòü íàì î ðåçóëüòàòàõ.
|
|
#8
|
|||
|
|||
Äà è åùå Âû íå óêàçûâàåòå åñòü ëè ó Âàøåé æåíû íàðóøåíèÿ ïåðåäâèæåíèÿ, ñîõðàíåíà ëè ñèëà â íîãàõ, åñòü ëè îíåìåíèå, ñíèæåíèå ÷óâñòâèòåëüíîñòè, òðîôè÷åñêèå èçìåíåíèÿ êîæè íèæíèõ êîíå÷íîñòåé. Èëè êðîìå áîëåé å¸ áîëüøå íè÷åãî íå áåñïîêîèò?
|
#9
|
|||
|
|||
Öèòàòà:
Àíàìíåç ÑÄ 1 òèïà - 4,5 ãîäà, ïðè ïëîõîé êîìïåíñàöèè - â ñàìûé ðàç. Â12-ÄÀ (ôóíèêóëÿðíûé ìèåëîç!) âðÿä ëè áóäåò íà ïåðâîì ïëàíå ó æåíùèíû 25 ëåò ñ òàêèì àíàìíåçîì. |
#10
|
|||
|
|||
Îïèñûâàþ ñèòóàöèþ ïîäðîáíî:
Ïåðåëîì íàçûâàåòñÿ "Äåêîìïðåññèîííûé" 1-ãî ïîÿñíè÷íîãî. Âñå ëå÷åíèå ñâåëîñü ê òîìó, ÷òî îíà ïðîëåæàëà ïîëãîäà äîìà, ñ âàëèêîì ïîä ïîÿñíèöåé. ×åðåç 3 òðè ìåñÿöà ïîñòàâèëè äèàãíîç ñàõàðíûé äèàáåò 1-ãî òèïà. Óðîâåíü ñàõàðà â êðîâè äåðæèòñÿ íà óðîâíå 10-15 åä. ×åðåç äâà ãîäà íà÷àëè áîëåòü èêðû, îñîáåííî ïðè äëèòåëüíûõ íàãðóçêàõ ïðè õîäüáå è ïîÿâèëàñü ñëàáîñòü â íîãàõ, ñåé÷àñ ñëàáîñòü è áîëè ïðè õîäüáå îñëàáëè. Ñåé÷àñ èêðû è ãîëåíü áîëÿò áîëüøå äíåì è ïðè õîäüáå è ñèäÿ, ñòóïíè áîëÿò âå÷åðîì, êîãäà íàõîäÿòñÿ â ñïîêîéíîì ñîñòîÿíèè. Òàê æå ïîÿâèëèñü áîëè â ïîÿñíèöå ïðè äîëãîì ñèäåíèè. Ïåðèîäè÷åñêè ïîÿâëÿåòñÿ æãó÷àÿ áîëü ÷àùå â ñòóïíÿõ è ïàëüöàõ íîã. Ïåðèîäè÷åñêè òåðÿåòñÿ ÷óâñòâèòåëüíîñòü ïàëüöåâ íîã. Ïåðèîäè÷åñêè ïîÿâëÿåòñÿ îíåìåíèå, ñóäîðãè. Ïåðèîäè÷åñêè áûâàþò ïðîñòðåëû îò ïîÿñíèöû â ïÿòêó. ÌÐÒ íå äåëàëè. Ñåðüåçíûõ îáñëåäîâàíèé ïðàêòè÷åñêè íèêàêèõ íå áûëî. Ïî÷åìó ñîáñòâåííî è îáðàùàþñü ê Âàì, ò.ê. â íàøåé ïîëèêëèíèêå ìîæíî ñêàçàòü ÷òî íè÷åãî èç îáñëåäîâàíèé ñäåëàòü íåëüçÿ, íåâðîëîãà íåò â ïðèíöèïå, êàê è ìíîãèõ äðóãèõ âðà÷åé. À åñëè è îáðàùàòüñÿ çà íàïðàâëåíèåì, òî äèàãíîç ëó÷øå ñàìîìó çíàòü - èíà÷å òî÷íî íå òóäà çàøëþò (ïðîâåðåíî íà ëþäÿõ). |
#11
|
|||
|
|||
Öèòàòà:
|
#12
|
|||
|
|||
Öèòàòà:
Öèòàòà:
Öèòàòà:
Íåëüçÿ, âïðî÷åì, èñêëþ÷èòü è "âêëàä" ïîçâîíî÷íèêà â ýòó ïðîáëåìó. ß áû ÌÐÒ âñ¸ æå ñäåëàë, òðàâìà-òî ñåðüåçíàÿ. Íî ñàìîå ãëàâíîå - ýòî ÊÎÌÏÅÍÑÀÖÈß ÄÈÀÁÅÒÀ. Ãîðîä Ïóøêèí íå òàê äàëåêî îò Ìîñêâû, à â Ìîñêâå ìíîãî ãðàìîòíûõ ýíäîêðèíîëîãîâ (è ïðèìåðîì òîìó íàø ôîðóì). Íà÷àòü - ñ ýíäîêðèíîëîãà, ÎÁÓ×ÅÍÈß è ïîäáîðà ñõåìû òåðàïèè. Áåç êîìïåíñàöèè äèàáåòà ëå÷èòü àíãèîïàòèþ, íåéðîïàòèþ ÍÅÂÎÇÌÎÆÍÎ. Óäà÷è! |
#13
|
||||
|
||||
Öèòàòà: Â12-ÄÀ (ôóíèêóëÿðíûé ìèåëîç!) âðÿä ëè áóäåò íà ïåðâîì ïëàíå ó æåíùèíû 25 ëåò ñ òàêèì àíàìíåçîì.
Óâàæàåìûé Àíòîí Âëàäèìèðîâè÷! 2 òåçèñîâ ïî òåìå: Endocr Pract. 1995;1(6):393-4. Nondiabetic neuropathy in a patient with diabetes. Bell MB FACE DS. Department of Medicine, University of Alabama at Birmingham, School of Medicine, Birmingham, Alabama. A case of peripheral neuropathy in a patient with diabetes who had atypical clinical findings is presented. Because of the atypical initial manifestations and short duration of insulin-dependent diabetes, another cause of the neuropathy was suspected. The presence of vitiligo, hypothyroidism, and diabetes prompted a search for evidence of pernicious anemia. Despite a normal blood cell count, the diagnosis of pernicious anemia was confirmed on the basis of an increased serum gastrin level and antiparietal cell antibody titer. Treatment with vitamin B12 resulted in an arrest, but not a reversal, of the signs of peripheral neuropathy. In patients with diabetes, vitamin B12 deficiency should be suspected; its early diagnosis and treatment are important in minimizing neurologic damage. Diabet Med. 2000 Oct;17(10):749-51. Prevalence of pernicious anaemia in patients with Type 1 diabetes mellitus and autoimmune thyroid disease. Perros P, Singh RK, Ludlam CA, Frier BM. Department of Diabetes, Royal Infirmary, Edinburgh, Scotland, UK AIMS: To determine the prevalence of pernicious anaemia in patients with Type 1 diabetes mellitus and autoimmune thyroid disease. METHODS: A randomly selected asymptomatic group of 63 patients with Type 1 diabetes who also had autoimmune thyroid disease was studied. Blood samples were taken and assayed for serum B12. Those subjects with serum B12 concentrations below the reference range had a further blood sample taken for determination of intrinsic factor antibody. RESULTS: One patient had been diagnosed previously to have pernicious anaemia. Three patients had low serum B12 concentration and positive intrinsic factor antibody, confirming the diagnosis of pernicious anaemia. The prevalence of pernicious anaemia in this population with Type 1 diabetes and concomitant autoimmune thyroid disease was 6.3%. In female patients the prevalence of pernicious anaemia was 8.5%. |
#14
|
|||
|
|||
Öèòàòà:
Íà÷àòü íàäî ñ êîìïåíñàöèè ñàõ. äèàáåòà.  ïðèíöèïå, ïàðàëëåëüíî ìîæíî ðåøàòü âîïðîñ äèô.äèàãíîñòèêè ìåæäó äèàáåòè÷ñêîé àíãèîïàòèåé (îñìîòð õèðóðãà è ÓÇÄà àðòåðèé íèæíèõ êîíå÷íîñòåé èëè äóïëåêñíîå èõ ñêàíèðîâàíèå), ïîëèíåéðîïàòèåé (íåâðîëîã è ñòèìóëÿöèîííàÿ ýëåêòðîìèîãðàôèÿ íèæíèõ êîíå÷íîñòåé) è ïîñëåäñòâèÿìè òðàâìû ïîÿñíè÷íîãî îòäåëà ïîçâîíî÷íèêà (ÊÒ ïîðàæåííîãî ñåãìåíòà èëè ÌÐÒ). Õîòÿ íà ìîé âçãëÿä, âåðîÿòíåå âñåãî ñî÷åòàíèå äèàáåòè÷åñêèõ àíãèî- è ïîëèíåéðîïàòèé. Íî ñ äèàáåòîì íå çàòÿãèâàéòå! Ñðî÷íî îáðàòèòåñü ê ýíäîêðèíîëîãó. È ëó÷øå â Ìîñêâå. |
#15
|
|||
|
|||
Ðàñïðîñòðàíåííîñòü Â12-äåôèöèòíîé àíåìèè ñðåäè äèàáåòèêîâ 1 òèïà - 6-8%
![]() Èíòåðåñíî ìíåíèå Ãàëèíû Àôàíàñüåâíû. Êàê îíî â æèçíè. Âàì, Âàäèì Âàëåðüåâè÷, êàê âñåãäà ñïàñèáî çà ññûëêè! |